These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient. Kulick SK; Kramer DA Ann Emerg Med; 1993 Mar; 22(3):610-2. PubMed ID: 8192712 [TBL] [Abstract][Full Text] [Related]
16. [Isolated hyperammonemia. A frequent consequence of treatment with sodium valproate]. Warter JM; Marescaux C; Rumbach L; Galmiche J; Micheletti G; Koehl C; Imler M Nouv Presse Med; 1981 Nov; 10(41):3406-7. PubMed ID: 6795590 [No Abstract] [Full Text] [Related]
17. [Sodium valproate, hyperammonemia and hepatic encephalopathy]. Imler M; Warter JM; Marescaux C Gastroenterol Clin Biol; 1982 Dec; 6(12):1042. PubMed ID: 6819177 [No Abstract] [Full Text] [Related]
18. [Carglumic acid for treatment of valproic acid-induced hyperammonaemia in a paediatric patient]. Gramage Caro T; Vélez-Díaz-Pallarés M; Serna Pérez J; Bermejo Vicedo T Farm Hosp; 2012; 36(5):437-8. PubMed ID: 22858088 [No Abstract] [Full Text] [Related]
19. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579 [TBL] [Abstract][Full Text] [Related]
20. Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases. Zaccara G; Paganini M; Campostrini R; Arnetoli G; Zappoli R; Moroni F Eur Neurol; 1984; 23(2):104-12. PubMed ID: 6426961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]